. 2020 Apr 21;25(8):1921. doi: 10.3390/molecules25081921

Table 2.

The mean plasma concentration of lipid peroxidation products in SAH-patients with regard to neurological conditions and gender; ^a p < 0.05 in comparison with patients on the first day after SAH.

	Parameters	F₂-isoprostanes [ng/ml]		Neuroprostanes [ng/ml]		4-HNE [nmol/ml]		4-HHE [pmol/ml]		MDA [nmol/ml]		4-ONE [pmol/ml]
	Day	1st	6–8th	1st	6–8th	1st	6–8th	Day	1st	6–8th	1st	6–8th	1st
Focal signs	/-/ n = 25	1.12 ± 0.55	0.86 ± 0.30 ^a	6.11 ± 2.62	3.88 ± 2.17 ^a	0.57 ± 0.39	0.28 ± 0.21 ^a	3.36 ± 1.58	3.65 ± 1.51	7.05 ± 4.98	5.74 ± 3.88	0.19 ± 0.15	0.15 ± 0.12
Focal signs	/+/ n = 5	1.17 ± 0.85	0.71 ± 0.41	7.11 ± 2.65	4.14 ± 1.08 ^a	0.94 ± 0.62	0.24 ± 0.14 ^a	2.90 ± 1.03	3.20 ± 1.47	8.90 ± 6.25	6.63 ± 4.82	0.20 ± 0.13	0.13 ± 0.03
Hunt-Hess scale	/1/ n = 19	1.13 ± 0.49	0.85 ± 0.40 ^a	6.25 ± 2.82	3.75 ± 1.83 ^a	0.62 ± 0.45	0.25 ± 0.16 ^a	3.51 ± 1.87	3.78 ± 1.41	6.22 ± 4.37	5.17 ± 3.07	0.15 ± 0.11	0.14 ± 0.10
Hunt-Hess scale	/2-4/ n = 11	1.11 ± 0.78	0.84 ± 0.37	6.04 ± 2.22	4.36 ± 2.71	0.69 ± 0.49	0.34 ± 0.26 ^a	3.05 ±1.30	2.84 ± 1.14	9.04 ± 5.46	7.74 ± 5.17	0.25 ± 0.18	0.17 ± 0.15
WFNS	/1/ n = 23	1.02 ± 0.50	0.83 ± 0.42	6.02 ± 2.72	4.08 ± 2.26	0.66 ± 0.47	0.29 ± 0.22 ^a	3.17 ± 1.48	3.42 ± 1.27	6.31 ± 4.19	5.73 ± 3.51	0.19 ± 0.14	0.16 ± 0.11
WFNS	/2-4/ n = 7	1.32 ± 0.76	0.83 ± 0.32	6.42 ± 2.00	3.36 ± 1.17 ^a	0.60 ± 0.38	0.25 ± 0.13 ^a	3.39 ± 1.17	3.87 ± 1.35	9.28 ± 6.59	6.98 ± 5.22	0.19 ± 0.16	0.10 ± 0.09
Fisher scale	/1-2/ n = 11	1.05 ± 0.57	0.78 ± 0.44	6.36 ± 3.42	4.00 ± 2.12 ^a	0.66 ± 0.46	0.30 ± 0.20 ^a	4.11 ± 1.79	4.34 ± 1.99	7.47 ± 4.99	4.64 ± 3.12	0.15 ± 0.12	0.15 ± 0.10
Fisher scale	/3-4/ n = 19	1.13 ± 0.61	0.86 ± 0.37	5.99 ± 2.04	3.89 ± 2.12 ^a	0.64 ± 0.45	0.27 ± 0.21 ^a	2.85 ± 1.15	3.04 ± 1.21	6.85 ± 5.03	6.82 ± 4.24	0.21 ± 0.15	0.15 ± 0.12
Brain edema	/-/ n = 11	1.11 ± 0.54	0.89 ± 0.44	5.63 ± 1.65	3.73 ± 1.45 ^a	0.71 ± 0.53	0.23 ± 0.19 ^a	4.28 ± 1.64	3.93 ± 1.43	6.88 ± 5.36	5.07 ± 3.73	0.14 ± 0.13	0.16 ± 0.10
Brain edema	/+/ n = 19	1.09 ± 0.62	0.79 ± 0.30 ^a	6.42 ± 2.98	4.05 ± 2.42 ^a	0.62 ± 0.42	0.31 ± 0.20 ^a	2.57 ± 1.35	3.33 ± 1.60	7.13 ± 4.87	6.51 ± 4.09	0.21 ± 0.15	0.15 ± 0.12
Hematoma	/-/ n = 25	1.09 ± 0.55	0.88 ± 0.40	6.16 ± 2.67	3.73 ± 1.63 ^a	0.59 ± 0.44	0.26 ± 0.15 ^a	3.53 ± 1.41	3.75 ± 1.31	6.64 ± 5.02	5.40 ± 3.61	0.16 ± 0.12	0.13 ± 0.09
Hematoma	/+/ n = 5	1.14 ± 0.85	0.66 ± 0.35	5.85 ± 1.97	5.22 ± 4.08	0.92 ± 0.44	0.39 ± 0.35	1.84 ± 0.40	2.38 ± 0.50	8.92 ± 4.51	9.74 ± 4.34	0.30 ± 0.20	0.29 ± 0.18
Complications	/-/ n = 25	1.16 ± 0.56	0.89 ± 0.37	6.32 ± 2.59	3.80 ± 1.90 ^a	0.64 ± 0.46	0.24 ± 0.12 ^a	3.42 ± 1.26	3.74 ± 1.74	7.40 ± 5.24	5.92 ± 3.96	0.18 ± 0.14	0.13 ± 0.09
Complications	/+/ n = 5	0.57 ± 0.51	0.33 ± 0.04	5.00 ± 2.22	4.56 ± 2.99	0.71 ± 0.38	0.46 ± 0.38 ^a	1.32 ± 0.34	2.03 ± 0.56	5.47 ± 3.06	6.70 ± 4.42	0.23 ± 0.14	0.22 ± 0.17
Gender	/W/ n = 21	0.98 ± 0.54	0.78 ± 0.38	6.36 ± 2.78	3.94 ± 1.90 ^a	0.67 ± 0.42	0.25 ± 0.16 ^a	3.01 ± 1.60	3.33 ± 1.63	6.89 ± 4.94	6.17 ± 4.02	0.16 ± 0.13	0.14 ± 0.10
Gender	/M/ n = 9	1.38 ± 0.62	0.92 ± 0.42 ^a	5.30 ± 1.40	3.91 ± 2.67	0.66 ± 0.42	0.35 ± 0.26	3.76 ± 2.19	4.01 ± 2.00	7.53 ± 5.28	5.78 ± 4.13	0.25 ± 0.16	0.18 ± 0.16

W-women; M-men.